CT引导下125I放射性粒子治疗脊柱转移性肿瘤的临床疗效

Objective: The purpose of this study was to examine the safety and clinical efficacy of computedtomography (CT)-guided radioactive iodine-125 ( 125 I) seed implantation treatment in patients
with spinal metastatic tumors.
Methods: We retrospectively analyzed 20 cases of spinal metastatic tumors, including nine men
and eleven women aged 50–79 years (mean age: 61.1 years). We used treatment planning system
(TPS) to construct three-dimensional images of the spinal metastatic tumors and to determine what
number and dose rate distribution to use for the 125 I seeds. The matched peripheral dose of the 125 I
seed implantation was 90–130 Gy. Twenty-four spinal metastatic tumors were treated by CT-guided
radioactive 125 I seed implantation. A median of 19 (range: 4–43) 125 I seeds were implanted.
Results: Twenty cases were followed for a median of 15.3 months (range: 7–32 months). The
rate of pain relief was 95%. The median control time for all of the patients was 12.5 months.
The 3-, 6-, and 12-month cumulative local control rates were 100%, 95%, and 60%, respec-
tively. The median survival time for all of the patients was 16 months. The cumulative 6- and
12-month survival rates were 100% and 78.81%, respectively. No major complications were
observed. No 125 I seeds were lost or migrated to other tissues or organs.
Conclusion: CT-guided radioactive 125 I seed implantation is a safe, effective, and minimally
invasive method for the treatment of patients with spinal metastatic tumors. It is a possible
alternative therapy for the treatment of spinal metastases.
Keywords: spinal metastatic tumor, iodine isotopes, computed tomography guided, interven-
tional treatment